I sure hope you're right, astoria, as I have a lot riding on PSD. I was well up a few months ago but now I'm well down. I can't say I'm as confident as you, but I haven't given up. These are my thoughts on the current situation:
- Cash remains a big problem. They acquired CDS, along with a significant increase in cash burn, but don't seem to have received the return they expected from Retisert. Poor Retisert sales seems the logical explanation for the surprise rights issue to raise capital.
- I'm concerned that directors are not buying, even at these low levels. I can only hope that, as you've claimed, this is because they possess too much inside information on good news to come, but I am not confident that that is the reason.
- I have big doubts about the state of Biosilicon drug delivery. We've heard nothing of the top 5 pharma for ages, and very little at all on progress. They've been working on it for 6 or 7 years now, so I think there must be significant technical problems.
- On GR's departure, he resigned only shortly after the SP plummeted to the low 0.30s. It's hard to believe that this was how he wanted to go out after founding the company and running it for so long.
- My hopes at present rest with Brachysil, which does look the goods on what we know, Retisert, which may improve as it becomes more widely known, and Medidur, which is in phase III trials. These alone will see a good recovery in the share price if they are successful, which is why I'm hanging in there.
Pezz
PSD
psivida limited
